

Bijlage 2 – referenties

Hoofdstuk 4: Beoordeling voor intensive care opname

1. de Montmollin E, Tandjaoui-Lambiotte Y, Legrand M, Lambert J, Mokart D, Kouatchet A, et al. Outcomes in critically ill cancer patients with septic shock of pulmonary origin. *Shock*. 2013 Mar;39(3):250-4.
2. Austin CA, Hanzaker C, Stafford R, Mayer C, Culp L, Lin FC, Chang L. Utilization of rapid response resources and outcomes in a comprehensive cancer center*. *Crit Care Med*. 2014 Apr;42(4):905-9.
3. Song JU, Suh GY, Park HY, Lim SY, Han SG, Kang YR, Kwon OJ, Woo S, Jeon K. Early intervention on the outcomes in critically ill cancer patients admitted to intensive care units. *Intensive Care Med*. 2012;38(9):1505-13.
4. Bokhari SW, Munir T, Memon S, et al.: Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission. *Annals of hematology* 2010; 89: 505-12.
5. Young RS, Gobel BH, Schumacher M, Lee J, Weaver C, Weitzman S. Use of the modified early warning score and serum lactate to prevent cardiopulmonary arrest in hematology-oncology patients: a quality improvement study. *Am J Med Qual* 2014 Nov-Dec;29(6):530-7.
6. Parmar A, Richardson H, McKinlay D, et al.: Medical emergency team involvement in patients hospitalized with acute myeloid leukemia. *Leukemia & lymphoma* 2013; 54(10):2236-42
7. Lee DS, Suh GY, Ryu JA, Chung CR, Yang JH, Park CM, Jeon K. Effect of Early Intervention on Long-Term Outcomes of Critically Ill Cancer Patients Admitted to ICUs. *Crit Care Med*. 2015 Mar 23. [Epub ahead of print]
8. Azoulay E, Mokart D, Pene F, et al.: Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en reanimation onco-hematologique study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013; 31: 2810-8.
9. Lengline E, Raffoux E, Lemiale V, Darmon M, Canet E, Boissel N, et al. Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. *Leuk Lymphoma*. 2012 Jul;53(7):1352-9.
10. Mokart D, Lambert J, Schnell D, Fouché L, Rabbat A, Kouatchet A, Lemiale V, Vincent F, Lengliné E, Bruneel F, Pene F, Chevret S, Azoulay E. Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. *Leuk Lymphoma*. 2013;54(8):1724-9.
11. Benoit DD, Vandewoude KH, Decruyenaere JM, et al.: Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. *Critical care medicine* 2003; 31: 104-12.
12. Merz TM, Schar P, Buhlmann M, et al.: Resource use and outcome in critically ill patients with hematological malignancy: a retrospective cohort study. *Critical care* 2008; 12: R75.

13. Hill QA, Kelly RJ, Patalappa C, et al.: Survival of patients with hematological malignancy admitted to the intensive care unit: prognostic factors and outcome compared to unselected medical intensive care unit admissions, a parallel group study. *Leukemia & Lymphoma* 2012; 53: 282-8.
14. Aygencel G, Turkoglu M, Sucak GT, et al.: Prognostic factors in critically ill cancer patients admitted to the intensive care unit. *J Crit Care* 2014; 29: 618-26.
15. Azoulay E, Mokart D, Pène F, et al.: Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium. *J Clin Oncol* 2013; 31: 2810-8.
16. McGrath S, Chatterjee F, Whiteley C, et al.: ICU and 6-month outcome of oncology patients in the intensive care unit. *QJM : monthly journal of the Association of Physicians* 2010; 103: 397-403.
17. Lim Z, Pagliuca A, Simpson S, et al.: Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data. *British journal of haematology* 2007; 136: 448-50.
18. Ferra C, Marcos P, Misis M, et al.: Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experience. *International journal of hematology* 2007; 85: 195-202.
19. van Vliet M, Verburg IWM, van den Boogaard M, et al.: Trends in admission prevalence, illness severity and survival of haematological patients treated in Dutch intensive care units. *Intensive care medicine* 2014; 40: 1275-84.
20. Azoulay E, Pène F, Darmon M, et al. Managing critically ill hematology patients: Time to think differently. *Blood reviews* 2015; 29: 359-67
21. Hill QA: Intensify, resuscitate or palliate: decision making in the critically ill patient with haematological malignancy. *Blood reviews* 2010; 24: 17-25.
22. Lamia B, Hellot MF, Girault C, et al.: Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU. *Intensive care medicine* 2006; 32: 1560-8.
23. Magid T, Haase N, Andersen JS, et al.: Intensive care of haematological patients. *Danish medical journal* 2012; 59: A4395.
24. Horster S, Stemmler HJ, Mandel PC, et al.: Mortality of patients with hematological malignancy after admission to the intensive care unit. *Onkologie* 2012; 35: 556-61.
25. Nishida K, Palalay MP: Prognostic factors and utility of scoring systems in patients with hematological malignancies admitted to the intensive care unit and required a mechanical ventilator. *Hawaii medical journal* 2008; 67: 264-9.
26. McCaughey C, Blackwood B, Glackin M, et al.: Characteristics and outcomes of haematology patients admitted to the intensive care unit. *Nursing in critical care* 2013; 18: 193-9.

27. Thiery G, Azoulay E, Darmon M, Ciroidi M, De Miranda S, Levy V, et al. Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. *J Clin Oncol*. 2005 Jul 1;23(19):4406-13.
28. Fèrra C, Marcos P, Misis M et al.: Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experience. *Int J hematol* 2007; 85: 195-202
29. Bird GT, Farquhar-Smith P, Wigmore T, et al.: Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. *British journal of anaesthesia* 2012; 108: 452-9.
30. Park MR, Jeon K, Song JU, et al.: Outcomes in critically ill patients with hematologic malignancies who received renal replacement therapy for acute kidney injury in an intensive care unit. *J Crit Care* 2011; 26: 107 e1-6.
31. Namendys-Silva SA, Gonzalez-Herrera MO, Garcia-Guillen FJ, et al.: Outcome of critically ill patients with hematological malignancies. *Annals of hematology* 2013; 92: 699-705.
32. Price KJ, Cardenas-Turanzas M, Lin H, et al.: Prognostic indicators of mortality of mechanically ventilated patients with acute leukemia in a comprehensive cancer center. *Minerva anesthesiologica* 2013; 79: 147-55.
33. Unselde S, Schuepbach RA, Maggiorini M: ICU, hospital and one year mortality of patients suffering from solid or haematological malignancies. *Swiss medical weekly* 2013; 143: w13741.
34. Van Vliet M, van den Boogaard M, Donnelly JP et al.: Long-term health related quality of life following intensive care during treatment for haematological malignancies. *PLoS One* 2014; 9(1): e87779
35. Afessa B, Azoulay E: Critical care of the hematopoietic stem cell transplant recipient. *Critical care clinics* 2010; 26: 133-50.
36. Geerse DA, Span LF, Pinto-Sietsma SJ, et al.: Prognosis of patients with haematological malignancies admitted to the intensive care unit: Sequential Organ Failure Assessment (SOFA) trend is a powerful predictor of mortality. *European journal of internal medicine* 2011; 22: 57-61.
37. Vandijck DM, Depuydt PO, Offner FC, et al.: Impact of organ dysfunction on mortality in ICU patients with hematologic malignancies. *Intensive care medicine* 2010; 36: 1744-50.

Hoofdstuk 5: Beleid op de intensive care afdeling (IC periode)

1. Wermke M, Schiemanck S, Hoffken G, Ehninger G, Bornhauser M, Illmer T. Respiratory failure in patients undergoing allogeneic hematopoietic SCT--a randomized trial on early non-invasive ventilation based on standard care hematology wards. *Bone Marrow Transplant*. 2012 Apr;47(4):574-80.
2. Gristina GR, Antonelli M, Conti G, Ciarlone A, Rogante S, Rossi C, et al. Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observational survey. *Crit Care Med*. 2011 Oct;39(10):2232-9

3. Molina R, Bernal T, Borges M, Zaragoza R, Bonastre J, Granada RM, et al. Ventilatory support in critically ill hematology patients with respiratory failure. *Crit Care*. 2012;16(4):R133.
4. Depuydt PO, Benoit DD, Vandewoude KH, Decruyenaere JM, Colardyn FA. Outcome in noninvasively and invasively ventilated hematologic patients with acute respiratory failure. *Chest*. 2004 Oct;126(4):1299-306.
5. Groeger JS, White P, Jr., Nierman DM, Glassman J, Shi W, Horak D, et al. Outcome for cancer patients requiring mechanical ventilation. *J Clin Oncol*. 1999 Mar;17(3):991-7.
6. Price KJ, Cardenas-Turanzas M, Lin H, Roden L, Nigam R, Nates JL. Prognostic indicators of mortality of mechanically ventilated patients with acute leukemia in a comprehensive cancer center. *Minerva Anestesiol*. 2013 Feb;79(2):147-55.
7. Soares M, Salluh JI, Azoulay E. Noninvasive ventilation in patients with malignancies and hypoxemic acute respiratory failure: a still pending question. *J Crit Care*. 2010 Mar;25(1):37-8.
8. Amado-Rodríguez L, Bernal T, López-Alonso I, Blázquez-Prieto J, García-Prieto E, Albaiceta GM. Impact of Initial Ventilatory Strategy in Hematological Patients With Acute Respiratory Failure: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2016 Jul;44(7):1406-13.
10. den Boer S, de Keizer NF, de Jonge E. Performance of prognostic models in critically ill cancer patients - a review. *Crit Care*. 2005 Aug;9(4):R458-63.
11. Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en reanimation onco-hematologique study. *J Clin Oncol*. 2013 Aug 1;31(22):2810-8.
12. Bos MM, de Keizer NF, Meynaar IA, Bakhshi-Raiez F, de Jonge E. Outcomes of cancer patients after unplanned admission to general intensive care units. *Acta Oncol*. 2012 Sep;51(7):897-905.
13. Cornet AD, Issa AI, van de Loosdrecht AA, Ossenkoppele GJ, Strack van Schijndel RJ, Groeneveld AB. Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care. *Eur J Haematol*. 2005 Jun;74(6):511-6.
14. Vandijck DM, Benoit DD, Depuydt PO, Offner FC, Blot SI, Van Tilborgh AK, et al. Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. *Intensive Care Med*. 2008 May;34(5):847-55.
15. Bernal T, Pardavila EV, Bonastre J, Jarque I, Borges M, Bargay J, et al. Survival of hematological patients after discharge from the intensive care unit: a prospective observational study. *Crit Care*. 2013;17(6):R302.
16. Bayraktar UD, Shpall EJ, Liu P, Ciurea SO, Rondon G, de Lima M, et al. Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. *J Clin Oncol*. 2013 Nov 20;31(33):4207-14.

17. Jackson K, Mollee P, Morris K, Butler J, Jackson D, Kruger P, et al. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. *Leuk Lymphoma*. 2014 Jan;55(1):97-104.
18. Coutsouvelis J, Corallo CE, Dooley MJ, Foo J, Whitfield A. Implementation of a pharmacist-initiated pharmaceutical handover for oncology and haematology patients being transferred to critical care units. *Support Care Cancer*. 2010 Jul;18(7):811-6.
19. Nazer LH, Eljaber R, Rimawi D, Hawari FI. Adverse drug events resulting in admission to the intensive care unit in oncology patients: Incidence, characteristics and associated cost. *J Oncol Pharm Pract*. 2012 Dec 7.
20. Hoenigl M, Duettmann W, Raggam RB, Seeber K, Troppan K, Fruhwald S, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. *Antimicrob Agents Chemother*. 2013 Jul;57(7):3262-7.
21. Lecuyer L, Chevret S, Guidet B, Aegerter P, Martel P, Schlemmer B, et al. Case volume and mortality in haematological patients with acute respiratory failure. *Eur Respir J*. 2008 Sep;32(3):748-54.
22. van Vliet M, Verburg IW, van den Boogaard M, de Keizer NF, Peek N, Blijlevens NM, et al. Trends in admission prevalence, illness severity and survival of haematological patients treated in Dutch intensive care units. *Intensive Care Med*. 2014 Sep;40(9):1275-84.

Hoofdstuk 6: Na intensive care opname (post-ic periode)

1. Endacott R, Chaboyer W, Edington J, Thalib L. Impact of an ICU Liaison Nurse Service on major adverse events in patients recently discharged from ICU. *Resuscitation*. 2010 Feb;81(2):198-201.
2. Green A, Edmonds L. Bridging the gap between the intensive care unit and general wards-the ICU Liaison Nurse. *Intensive Crit Care Nurs*. 2004 Jun;20(3):133-43.
3. McIntyre T, Taylor C, Eastwood GM, Jones D, Baldwin I, Bellomo R. A survey of ward nurses attitudes to the Intensive Care Nurse Consultant service in a teaching hospital. *Aust Crit Care*. 2012 May;25(2):100-9.
4. Ball C, Kirkby M, Williams S. Effect of the critical care outreach team on patient survival to discharge from hospital and readmission to critical care: non-randomised population based study. *BMJ*. 2003 Nov 1;327(7422):1014.
5. Le RQ, Bevans M, Savani BN, Mitchell SA, Stringaris K, Koklanaris E, et al. Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. *Biol Blood Marrow Transplant*. 2010 Aug;16(8):1162-70.
6. van Vliet M, van den Boogaard M, Donnelly JP, Evers AW, Blijlevens NM, Pickkers P. Long-term health related quality of life following intensive care during treatment for haematological malignancies. *PLoS One*. 2014;9(1):e87779.

7. Kentish-Barnes N, Lemiale V, Chaize M, Pochard F, Azoulay E. Assessing burden in families of critical care patients. *Crit Care Med*. 2009 Oct;37(10 Suppl):S448-56.
8. Connolly B, Douiri A, Steier J, Moxham J, Denehy L, Hart N. A UK survey of rehabilitation following critical illness: implementation of NICE Clinical Guidance 83 (CG83) following hospital discharge. *BMJ Open*. 2014;4(5):e004963.
9. Gosselink R, Bott J, Johnson M, Dean E, Nava S, Norrenberg M, et al. Physiotherapy for adult patients with critical illness: recommendations of the European Respiratory Society and European Society of Intensive Care Medicine Task Force on Physiotherapy for Critically Ill Patients. *Intensive Care Med*. 2008 Jul;34(7):1188-99.

Hoofdstuk 7: Antimicrobieel beleid bij hemato-oncologische patiënten op de intensive care

7.1 Profylaxe en pre-emptieve behandeling

1. SWAB guidelines for antibacterial therapy of adult patients with sepsis. Dutch Working Party on Antibiotic Policy (SWAB). 2010. Opgehaald van <http://www.swab.nl>
2. SWAB richtlijn: selectieve decontaminatie bij patiënten op intensive care. Stichting werkgroep antibioticabeleid augustus 2014. (sd). Opgehaald van <http://www.swab.nl>
3. Engelhard D, Akova M, Boeck MJ et al. Bacterial infection prevention after hematopoietic cell transplantation. *Bone Marrow Transplant*. 2009;44(8):467-70.
4. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. *Clin Infect Dis*. 2011;52(4):56-93/427-31.
5. Maertens J, Marchetti O, Herbrecht K et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL3 - 2009 update. *Bone Marrow Transplant*. 2011;46(5):709-18.
6. Green H, Paul M, Vidal L et al. Prophylaxis of *Pneumocystis pneumonia* in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. *Mayo Clin Proc*. 2007;82(9):1052-9.
7. Neumann S, Krause SW, Maschmeijer G et al. Primary prophylaxis of bacterial infections and *Pneumocystis jirovecii pneumonia* in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol*. 2013;92(4):433-42.
8. Zaia J, Baden L, Boeckh MJ et al. Viral disease prevention after hematopoietic cell transplantation. *Bone Marrow Transplant*. 2009;44(8):471-82.
9. Sandherr M, Hentrich M, von Lilienfeld-Toal M et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). *Ann Hematol*. 2015;94(9):1441-50.

7.2 Behandeling van febrile neutropenie

1. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):56-93/427-31.
2. SWAB guidelines for antibacterial therapy of adult patients with sepsis. Dutch Working Party on Antibiotic Policy (SWAB). 2010. Opgehaald van <http://www.swab.nl>
3. Clark OA, Lyman GH, Castro AA et al. Colony stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198-214.

7.3 Broncho alveolaire lavage

1. Azoulay E, Mokart D, Lambert J, Lemiale V, Rabbat A, Kouatchet A et al. Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med 2010; 182(8): 1038-1046.
2. Azoulay E, Mokart D, Rabbat A, Pene F, Kouatchet A, Bruneel F et al. Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data. Crit Care Med 2008; 36(1): 100-107.
3. Gruson D, Hilbert G, Portel L, Boiron JM, Bebear CM, Vargas F et al. Severe respiratory failure requiring ICU admission in bone marrow transplant recipients. Eur Respir J 1999; 13(4): 883-887.
4. Gruson D, Hilbert G, Valentino R, Vargas F, Chene G, Bebear C et al. Utility of fiberoptic bronchoscopy in neutropenic patients admitted to the intensive care unit with pulmonary infiltrates. Crit Care Med 2000; 28(7): 2224-2230.
5. Panda A, McArdle JR. To bronch or not to bronch? A recurring challenge in neutropenic patients with pulmonary infiltrates. Conn Med 2010; 74(2): 69-77.
6. Rabbat A, Chaoui D, Lefebvre A, Roche N, Legrand O, Lorut C et al. Is BAL useful in patients with acute myeloid leukemia admitted in ICU for severe respiratory complications? Leukemia 2008; 22(7): 1361-1367. doi: 10.1038/leu.2008.100
7. Cracco C, Fartoukh M, Prodanovic H, Azoulay E, Chenivresse C, Lorut C et al. Safety of performing fiberoptic bronchoscopy in critically ill hypoxemic patients with acute respiratory failure. Intensive Care Med 2013; 39(1): 45-52. doi: 10.1007/s00134-012-2687-9

Hoofdstuk 8: Transfusie van bloedproducten bij hematologische patiënten op de intensive care tijdens of na behandeling van een hematologische maligniteit

1. CBO, Richtlijn Bloedtransfusie. CBO richtlijn, 2011: p. 1-564.
2. Retter A, Wyncoll D, Pearse R, et al. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. Br J Haematol 2013; 160(4): 224-64

3. Hébert, P.C., et al., A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *New England Journal of Medicine*, 1999. 340(6): p. 409-417.
4. Gould S, Cimino MJ, Gerber DR. Packed red blood cell transfusion in the intensive care unit: limitation and consequences. *Am J Crit Care* 2007; 16(1): 39-48
5. McIntyre, L., et al., Is a restrictive transfusion strategy safe for resuscitated and critically ill trauma patients? *J Trauma*, 2004. 57(3): p. 563-8; discussion 568.
6. Hajjar, L.A., et al., Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. *JAMA*, 2010. 304(14): p. 1559-67.
7. Marik, P.E. and H.L. Corwin, Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. *Crit Care Med*, 2008. 36(9): p. 2667-74.
8. Carson, J.L., P.A. Carless, and P.C. Hebert, Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev*, 2012. 4: p. CD002042.
9. Deans, K.J., et al., Randomization in clinical trials of titrated therapies: unintended consequences of using fixed treatment protocols. *Crit Care Med*, 2007. 35(6): p. 1509-16.
10. Holst, L.B., et al., Lower versus higher hemoglobin threshold for transfusion in septic shock. *N Engl J Med*, 2014. 371(15): p. 1381-91.
11. Cook, D., et al., Dalteparin versus unfractionated heparin in critically ill patients. *N Engl J Med*, 2011. 364(14): p. 1305-14.
12. Strauss, R., et al., Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. *Crit Care Med*, 2002. 30(8): p. 1765-71.
13. Gajic, O., W.H. Dzik, and P. Toy, Fresh frozen plasma and platelet transfusion for nonbleeding patients in the intensive care unit: benefit or harm? *Crit Care Med*, 2006. 34(5 Suppl): p. S170-3.
14. McIntyre, L., A.T. Tinmouth, and D.A. Fergusson, Blood component transfusion in critically ill patients. *Current opinion in critical care*, 2013. 19(4): p. 326-333.
15. Stanworth, S.J., et al., Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. *Cochrane Database Syst Rev*, 2004(4): p. CD004269.
16. Stanworth, S.J., et al., A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. *New England Journal of Medicine*, 2013. 368(19): p. 1771-1780.
17. Wandt, H., et al., Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. *Lancet*, 2012. 380(9850): p. 1309-16.